Inventor · disambiguated record
Mazen Hanna
Also filed as: HANNA MAZEN · HANNA MAZEN H · HANNA MAZEN HERMIZ
30 granted patents·14 pending applications·1,073 citations·filing 1994–2021
97Inventor score
Files withHANNA MAZEN9GRUENENTHAL CHEMIE7THAR PHARMACEUTICALS INC6TRANSGENEX NANOBIOTECH INC6NEKTAR THERAPEUTICS3
Top patents by PatentIndex Score
44 records- 0198US8399023B2Crystallization method and bioavailabilityHANNA MAZEN·Filed 2010·Granted Mar 19, 2013·94 cites·28 claims
- 0297US9169279B2Crystallization method and bioavailabilityHANNA MAZEN·Filed 2012·Granted Oct 27, 2015·87 cites·9 claims
- 0397US8933057B2Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2013·Granted Jan 13, 2015·90 cites·28 claims
- 0497US5851453AMethod and apparatus for the formation of particlesUNIV BRADFORD·Filed 1994·Granted Dec 22, 1998·194 cites·25 claims
- 0595US6063138AMethod and apparatus for the formation of particlesBRADFORD PARTICLE DESIGN LTD·Filed 1995·Granted May 16, 2000·267 cites·22 claims
- 0694US5795594ASalmeterol xinafoate with controlled particle sizeGLAXO GROUP LTD·Filed 1994·Granted Aug 18, 1998·124 cites·15 claims
- 0792US6860907B1Method of particle formationNEKTAR THERAPEUTICA·Filed 2000·Granted Mar 1, 2005·57 cites·35 claims
- 0891US8241371B2Method of creating crystalline substancesHANNA MAZEN·Filed 2008·Granted Aug 14, 2012·19 cites·25 claims
- 0989US9340565B2Crystalline formsHANNA MAZEN·Filed 2011·Granted May 17, 2016·5 cites·20 claims
- 1087US8124603B2In vivo studies of crystalline forms of meloxicamHANNA MAZEN·Filed 2009·Granted Feb 28, 2012·4 cites·25 claims
- 1186US7115280B2Particle formation methods and their productsNEKTAR THERAPEUTICS UK LTD·Filed 2001·Granted Oct 3, 2006·21 cites·60 claims
- 1286US6440337B1Method and apparatus for the formation of particlesINHALE THERAPEUTIC SYST·Filed 1998·Granted Aug 27, 2002·61 cites·33 claims
- 1382US8486927B2Crystalline forms of lamotrigineHANNA MAZEN·Filed 2008·Granted Jul 16, 2013·3 cites·14 claims
- 1481US9334296B2Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2013·Granted May 10, 2016·4 cites·22 claims
- 1574US8980868B2Oral forms of a phosphonic acid derivativeHANNA MAZEN·Filed 2010·Granted Mar 17, 2015·2 cites·14 claims
- 1674US8389512B2In vivo studies of crystalline forms of meloxicamHANNA MAZEN·Filed 2012·Granted Mar 5, 2013·2 cites·43 claims
- 1770US6576262B1Methods and apparatus for particle formationNEKTAR THERAPEUTICS·Filed 1999·Granted Jun 10, 2003·27 cites·15 claims
- 1869US9120031B2Compositions of particulate coformulationHANNA MAZEN H·Filed 2006·Granted Sep 1, 2015·1 cites·4 claims
- 1968US10798955B2Compositions of particulate coformulationNEKTAR THERAPEUTICS·Filed 2017·Granted Oct 13, 2020·0 cites·17 claims
- 2066US10519176B2Crystalline formsGRUENENTHAL CHEMIE·Filed 2017·Granted Dec 31, 2019·0 cites·15 claims
- 2166US7150766B2Method of particle formationNEKTAR THERAPEUTICS UK LTD·Filed 2004·Granted Dec 19, 2006·11 cites·9 claims
- 2265US10323052B2Crystallization method and bioavailabilityGRUENENTHAL CHEMIE·Filed 2017·Granted Jun 18, 2019·0 cites·20 claims
- 2364US10093691B2Crystallization method and bioavailabilityGRUENENTHAL CHEMIE·Filed 2016·Granted Oct 9, 2018·0 cites·5 claims
- 2459US10526358B2Crystalline formsGRUENENTHAL CHEMIE·Filed 2018·Granted Jan 7, 2020·0 cites·18 claims
- 2558US9040535B2Crystalline molecular comlpexes of tadalafilTHAR PHARMACEUTICALS INC·Filed 2013·Granted May 26, 2015·0 cites·8 claims
- 2656US2017022225A1Novel crystalline formsTHAR PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2756US2003047824A1Method and apparatus for the formation of particlesBRADFORD PARTICLE DESIGN PLC·Filed 2002·Application pending·0 cites
- 2855US2017022226A1Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2952US2015366241A1Compositions of particulate coformulationNEKTAR THERAPEUTICS·Filed 2015·Application pending·0 cites
- 3051US8586587B2Crystalline molecular complex of tadalafil and methylparabenHANNA MAZEN·Filed 2010·Granted Nov 19, 2013·0 cites·9 claims
- 3150US2016016982A1Crystallization method and bioavailabilityTHAR PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3249US10195218B2Crystallization method and bioavailabilityGRUENENTHAL CHEMIE·Filed 2017·Granted Feb 5, 2019·0 cites·19 claims
- 3349US2023285442A1Use of oligochitosans and derivatives thereof for neutralizing viral agentsMOHAPATRA SUBHRA·Filed 2021·Application pending·0 cites
- 3448US9682091B2Oral forms of a phosphonic acid derivativeGRUENENTHAL CHEMIE·Filed 2015·Granted Jun 20, 2017·0 cites·9 claims
- 3548US2006073087A1Method and apparatus for the formation of particlesHANNA MAZEN H·Filed 2005·Application pending·0 cites
- 3646US2004071783A1Methods and apparatus for particle formationFiled 2003·Application pending·0 cites
- 3746US2002073511A1Method and apparatus for the formation of particlesFiled 2001·Application pending·0 cites
- 3844US11053254B2Crystalline forms of mitomycin C for treatment of cancerTRANSGENEX NANOBIOTECH INC·Filed 2019·Granted Jul 6, 2021·0 cites·31 claims
- 3943US2019083407A1Crystallization method and bioavailabilityGRUENENTHAL CHEMIE·Filed 2018·Application pending·0 cites
- 4039US2019292524A1Methods for cancer stem cell (csc) expansionTRANSGENEX NANOBIOTECH INC·Filed 2017·Application pending·0 cites
- 4135US11319311B2Crystalline forms of Actinomycin D for treatment of cancerTRANSGENEX NANOBIOTECH INC·Filed 2019·Granted May 3, 2022·0 cites·20 claims
- 4235US2022185767A1Novel ternary molecular complex of tamibarotene for cancer stem cells treatmentTRANSGENEX NANOBIOTECH INC·Filed 2020·Application pending·0 cites
- 4335US2020323949A1Molecular engineering of a novel ternary complex of actinomycin d for cancer stem cells treatmentTRANSGENEX NANOBIOTECH INC·Filed 2020·Application pending·0 cites
- 4430US2021002209A1Novel crystalline forms of tamibarotene for treatment of cancerTRANSGENEX NANOBIOTECH INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mazen Hanna files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →